Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with con- genital heart disease. J Am Coll Cardiol. 2002;39:1827 35. S4.4.2-62. Deal BJ, Mavroudis C, Backer CL, et al. Comparison of ana- tomic isthmus block with the modified right atrial maze proce- dure for late atrial tachycardia in Fontan patients. Circulation. 2002;106:575 9. S4.4.2-63. Rychik J, Veldtman G, Rand E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary sympo- sium. Pediatr Cardiol. 2012;33:1001 12. S4.4.2-64. Monagle P, Cochrane A, Roberts R, et al. A multicenter, random- ized trial comparing heparin/warfarin and acetylsalicylic acid as pri- mary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011;58:645 51. S4.4.2-65. McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associ- ated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol. 2013;61:346 53. 4.4.6. Severe PAH and Eisenmenger Syndrome 4.4.6.1. Severe PAH S4.4.6.1-1. D Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol. 2013;168:3797 801. CLINICAL STATEMENTS AND GUIDELINES S4.4.6.1-2. Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. 2014;113:147 55. S4.4.6.1-3. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic per- spective from a Dutch registry. Int J Cardiol. 2007;120:198 204. S4.4.6.1-4. Engelfriet PM, Duffels MGJ, M ller T, et al. 